Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat

In the United States, fibrin sealants have been used to achieve hemostasis for nearly two decades. Although their clinical utility was first demonstrated in cardiac surgery, their effectiveness and safety have since been demonstrated to extend to a wide array of procedures. Fibrin sealants typically...

Full description

Saved in:
Bibliographic Details
Published in:Reviews in urology 2015, Vol.17 (1), p.25-30
Main Authors: Albala, David M, Riebman, Jerome B, Kocharian, Richard, Ilie, Bogdan, Albanese, John, Shen, Jessica, Ovington, Liza, Batiller, Jonathan
Format: Article
Language:English
Subjects:
Original Research
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 30
container_issue 1
container_start_page 25
container_title Reviews in urology
container_volume 17
creator Albala, David M
Riebman, Jerome B
Kocharian, Richard
Ilie, Bogdan
Albanese, John
Shen, Jessica
Ovington, Liza
Batiller, Jonathan
description In the United States, fibrin sealants have been used to achieve hemostasis for nearly two decades. Although their clinical utility was first demonstrated in cardiac surgery, their effectiveness and safety have since been demonstrated to extend to a wide array of procedures. Fibrin sealants typically contain two components-fibrinogen and thrombin-that are combined and delivered simultaneously to a target bleeding site in order to achieve hemostasis. However, many commercial formulations contain other additional components, such as antifibrinolytic agents, that have been associated with adverse outcomes. This subanalysis compares the safety and effectiveness of a fibrin sealant versus an absorbable hemostat for achieving hemostasis during urologic procedures with mild to moderate bleeding.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4444771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1685747367</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1111-4ea3816207eb7f266a7025e3fded1ed2f6d3f358bfcd7fe294be787a68731e673</originalsourceid><addsrcrecordid>eNpVkMFKxDAURbNQnHH0FyRLN4UmaZPUhSCDOoLgZlyHpHnpRNqmJq0yf29xRtG7uYsL5_DeCVqSkrKME04W6DyltzwvWCGrM7SgPKeyquQSbTfQhTTq5BO2U_R9g6cY2tD4GqcpNhD3N9h5My84gW51P-I6dIOOYPGnH3dYmxSi0aYFvDuwxgt06nSb4PLYK_T6cL9db7Lnl8en9d1zNpA5WQGaScJpLsAIRznXIqclMGfBErDUccscK6VxtRUOaFUYEFJoLgUjwAVbodsDd5hMB7aGfoy6VUP0nY57FbRX_5fe71QTPlQxRwgyA66PgBjeJ0ij6nyqoZ3PhDAlRbgsRSHYt-vqr-tX8vNK9gXzXXHu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1685747367</pqid></control><display><type>article</type><title>Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat</title><source>Open Access: PubMed Central</source><creator>Albala, David M ; Riebman, Jerome B ; Kocharian, Richard ; Ilie, Bogdan ; Albanese, John ; Shen, Jessica ; Ovington, Liza ; Batiller, Jonathan</creator><creatorcontrib>Albala, David M ; Riebman, Jerome B ; Kocharian, Richard ; Ilie, Bogdan ; Albanese, John ; Shen, Jessica ; Ovington, Liza ; Batiller, Jonathan</creatorcontrib><description>In the United States, fibrin sealants have been used to achieve hemostasis for nearly two decades. Although their clinical utility was first demonstrated in cardiac surgery, their effectiveness and safety have since been demonstrated to extend to a wide array of procedures. Fibrin sealants typically contain two components-fibrinogen and thrombin-that are combined and delivered simultaneously to a target bleeding site in order to achieve hemostasis. However, many commercial formulations contain other additional components, such as antifibrinolytic agents, that have been associated with adverse outcomes. This subanalysis compares the safety and effectiveness of a fibrin sealant versus an absorbable hemostat for achieving hemostasis during urologic procedures with mild to moderate bleeding.</description><identifier>ISSN: 1523-6161</identifier><identifier>PMID: 26028998</identifier><language>eng</language><publisher>United States: MedReviews, LLC</publisher><subject>Original Research</subject><ispartof>Reviews in urology, 2015, Vol.17 (1), p.25-30</ispartof><rights>2015 MedReviews®, LLC 2015 MedReviews®, LLC</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444771/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444771/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26028998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Albala, David M</creatorcontrib><creatorcontrib>Riebman, Jerome B</creatorcontrib><creatorcontrib>Kocharian, Richard</creatorcontrib><creatorcontrib>Ilie, Bogdan</creatorcontrib><creatorcontrib>Albanese, John</creatorcontrib><creatorcontrib>Shen, Jessica</creatorcontrib><creatorcontrib>Ovington, Liza</creatorcontrib><creatorcontrib>Batiller, Jonathan</creatorcontrib><title>Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat</title><title>Reviews in urology</title><addtitle>Rev Urol</addtitle><description>In the United States, fibrin sealants have been used to achieve hemostasis for nearly two decades. Although their clinical utility was first demonstrated in cardiac surgery, their effectiveness and safety have since been demonstrated to extend to a wide array of procedures. Fibrin sealants typically contain two components-fibrinogen and thrombin-that are combined and delivered simultaneously to a target bleeding site in order to achieve hemostasis. However, many commercial formulations contain other additional components, such as antifibrinolytic agents, that have been associated with adverse outcomes. This subanalysis compares the safety and effectiveness of a fibrin sealant versus an absorbable hemostat for achieving hemostasis during urologic procedures with mild to moderate bleeding.</description><subject>Original Research</subject><issn>1523-6161</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkMFKxDAURbNQnHH0FyRLN4UmaZPUhSCDOoLgZlyHpHnpRNqmJq0yf29xRtG7uYsL5_DeCVqSkrKME04W6DyltzwvWCGrM7SgPKeyquQSbTfQhTTq5BO2U_R9g6cY2tD4GqcpNhD3N9h5My84gW51P-I6dIOOYPGnH3dYmxSi0aYFvDuwxgt06nSb4PLYK_T6cL9db7Lnl8en9d1zNpA5WQGaScJpLsAIRznXIqclMGfBErDUccscK6VxtRUOaFUYEFJoLgUjwAVbodsDd5hMB7aGfoy6VUP0nY57FbRX_5fe71QTPlQxRwgyA66PgBjeJ0ij6nyqoZ3PhDAlRbgsRSHYt-vqr-tX8vNK9gXzXXHu</recordid><startdate>2015</startdate><enddate>2015</enddate><creator>Albala, David M</creator><creator>Riebman, Jerome B</creator><creator>Kocharian, Richard</creator><creator>Ilie, Bogdan</creator><creator>Albanese, John</creator><creator>Shen, Jessica</creator><creator>Ovington, Liza</creator><creator>Batiller, Jonathan</creator><general>MedReviews, LLC</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2015</creationdate><title>Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat</title><author>Albala, David M ; Riebman, Jerome B ; Kocharian, Richard ; Ilie, Bogdan ; Albanese, John ; Shen, Jessica ; Ovington, Liza ; Batiller, Jonathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1111-4ea3816207eb7f266a7025e3fded1ed2f6d3f358bfcd7fe294be787a68731e673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Original Research</topic><toplevel>online_resources</toplevel><creatorcontrib>Albala, David M</creatorcontrib><creatorcontrib>Riebman, Jerome B</creatorcontrib><creatorcontrib>Kocharian, Richard</creatorcontrib><creatorcontrib>Ilie, Bogdan</creatorcontrib><creatorcontrib>Albanese, John</creatorcontrib><creatorcontrib>Shen, Jessica</creatorcontrib><creatorcontrib>Ovington, Liza</creatorcontrib><creatorcontrib>Batiller, Jonathan</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Reviews in urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Albala, David M</au><au>Riebman, Jerome B</au><au>Kocharian, Richard</au><au>Ilie, Bogdan</au><au>Albanese, John</au><au>Shen, Jessica</au><au>Ovington, Liza</au><au>Batiller, Jonathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat</atitle><jtitle>Reviews in urology</jtitle><addtitle>Rev Urol</addtitle><date>2015</date><risdate>2015</risdate><volume>17</volume><issue>1</issue><spage>25</spage><epage>30</epage><pages>25-30</pages><issn>1523-6161</issn><abstract>In the United States, fibrin sealants have been used to achieve hemostasis for nearly two decades. Although their clinical utility was first demonstrated in cardiac surgery, their effectiveness and safety have since been demonstrated to extend to a wide array of procedures. Fibrin sealants typically contain two components-fibrinogen and thrombin-that are combined and delivered simultaneously to a target bleeding site in order to achieve hemostasis. However, many commercial formulations contain other additional components, such as antifibrinolytic agents, that have been associated with adverse outcomes. This subanalysis compares the safety and effectiveness of a fibrin sealant versus an absorbable hemostat for achieving hemostasis during urologic procedures with mild to moderate bleeding.</abstract><cop>United States</cop><pub>MedReviews, LLC</pub><pmid>26028998</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1523-6161
ispartof Reviews in urology, 2015, Vol.17 (1), p.25-30
issn 1523-6161
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4444771
source Open Access: PubMed Central
subjects Original Research
title Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A29%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemostasis%20during%20urologic%20surgery:%20fibrin%20sealant%20compared%20with%20absorbable%20hemostat&rft.jtitle=Reviews%20in%20urology&rft.au=Albala,%20David%20M&rft.date=2015&rft.volume=17&rft.issue=1&rft.spage=25&rft.epage=30&rft.pages=25-30&rft.issn=1523-6161&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1685747367%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p1111-4ea3816207eb7f266a7025e3fded1ed2f6d3f358bfcd7fe294be787a68731e673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1685747367&rft_id=info:pmid/26028998&rfr_iscdi=true